MicroRNA-181a is elevated by 10-hydroxycamptothecin and represses lung carcinoma progression by downregulating FOXP1  

作　　者：LI PAN WENTING YI DONGMIN LIANG YULONG ZHAO RANRAN WANG PINGYU WANG YOUJIE LI JIAXUAN XIN YUNFEI YAN SHUYANG XIE 

机构地区：[1]Department of Biochemistry and Molecular Biology,Binzhou Medical University,Yantai,264003,China [2]Department of Medical Laboratory,Yantai Affiliated Hospital of Binzhou Medical University,Yantai,264100,China

出　　处：《BIOCELL》2022年第2期417-431,共15页生物细胞（英文）

基　　金：supported by the National Natural Science Foundation of China(Nos.81702296,81772281);the Shandong Science and Technology Committee(Nos.2017GSF18124,ZR2019PC019,ZR2019MH022);the Health Commission of Shandong Province(Nos.2017WS737,2019KJK014);the Shandong Province Taishan Scholar Project(No.ts201712067).

摘　　要：Tumor progression is usually characterized by proliferation,migration,and angiogenesis,which is essential for supplying both nutrients and oxygen to the tumor cells.Therefore,targeting angiogenesis has been considered a promising therapeutic strategy for cancer prevention and treatment.In the present study,we demonstrated that in addition to suppressing lung cancer cell proliferation and migration in vitro,10-hydroxycamptothecin(10-HCPT)is also capable of inhibiting angiogenesis in vivo with a miR-181a-dependent manner.Mechanistically,by upregulating miR-181a,which in turn downregulating FOXP1,10-HCPT can inhibit the PI3K/Akt/ERK signaling pathwaymediated angiogenesis.Furthermore,reduced levels of miR-181a have been found in both lung cancer cell lines and xenograft with concurrently elevated levels of FOXP1,VEGF,bFGF,and HDGF.Consistent with the findings from the in vitro experiments,miR-181a impairs neovascularization in our xenograft model.In summary,our findings have not only established the anti-oncogenic role of miR-181a in lung cancer angiogenesis but also suggest that 10-HCPT could be a potential therapeutic reagent for lung cancer treatment.

关 键 词：microRNA-181a 10-HYDROXYCAMPTOTHECIN ANGIOGENESIS Lung carcinoma 

分 类 号：R73[医药卫生—肿瘤]